However, a phase IIb trial of the PPAR gamma agonist pioglitazone failed to show efficacy in improving dysplasia, suggesting that iloprost’s mechanism is more complicated than solely PPAR gamma activation (26). This evidence concerns the gene PPARG and dysplasia.